期刊文献+

阿戈美拉汀治疗失眠障碍的研究进展 被引量:10

The Development of Studies on Agomelatin to Sleep Disorder
在线阅读 下载PDF
导出
摘要 失眠障碍是最常见的睡眠障碍,困扰着很多人的生活,目前对失眠障碍的治疗以苯二氮[艹卓]类药物应用最为广泛,但其不良反应较多,耐受性差。近年来,褪黑素受体激动剂成为治疗失眠障碍的研究热点,其代表药物有雷美替胺(也译为拉米替隆,Ramelteon)、他司美琼(Tasimelteon)及阿戈美拉汀(Agomelatine)等,本文综述了阿戈美拉汀的作用机制及其治疗失眠障碍的研究进展。 Insomnia disorder is the most common sleep disorder,which affects many people′s life.At present,benzodiazepine drugs are the most widely used in the treatment of insomnia disorder,but its side effects are more and the tolerance is poor.In recent years,melatonin receptor agonists have become a hot spot in the treatment of insomnia disorders,which represent the drugs of Remetimine(Ramelteon),Tasimelteon and Agomelatine,etc.This paper reviews the mechanism of Agomepratine and the progress in the treatment of insomnia disorders.
作者 张帆 合浩 冒才英 李晓霞 吕鑫 Zhang Fan;He Hao;Mao Caiying;Li Xiaoxia;Lyu Xin(Yunnan Psychiatry Hospital, Kunming 650224,China)
出处 《世界睡眠医学杂志》 2019年第5期688-690,共3页 World Journal of Sleep Medicine
关键词 阿戈美拉汀 褪黑素 失眠障碍 Agomelatin Melatonin Insomnia disorder
作者简介 张帆(1976-),男,医学,副主任医师,研究方向:临床精神病学,E-mail:1085156153@qq.com;通信作者:吕鑫,E-mail:791149126@qq.com.
  • 相关文献

参考文献2

二级参考文献33

  • 1Descamps A, Rousset C, Millan M J, et al. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture [J]. Psychopharmacology, 2009, 205 (1) : 93-106.
  • 2Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study [J]. Int J Neuropsychopharmacol, 2007, 10 (5) : 691-696.
  • 3Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severeMDD patients: a randomized, double-blind study[J]. Int Clin Psychopharmacol, 2010 Sep 18. [Epub ahead of print].
  • 4Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine [J]. J Clin Psychiatry, 2007, 68(11): 1723-1732.
  • 5Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients [J]. Hum Psychopharmacol, 2010, 25 (3) : 222-229.
  • 6Stein D J, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study[J]. J Clin Psyehopharrnaeol, 2008, 28 (5) : 561-566.
  • 7Leproult R, Van OA, L'hermite-Baleriaux M, et al. Phaseshifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men[J]. Clin Endocrinol (Oxf), 2005, 63 (3) : 298-304.
  • 8Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study [J]. Int Clin Psychol0harmacol, 2002, 17 (5):239-247.
  • 9Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder [J]. Eur Neuropsychopharrnacol, 2006, 16 (2) : 93-100.
  • 10Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR [J]. J Clin Psychopharmacol, 2008, 28 (3) : 329-333.

共引文献12

同被引文献71

引证文献10

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部